Palisade Bio Seeks Capital After Positive PALI-2108 Phase 1 Results

TL;DR

**PALI is raising a boatload of cash after some promising early-stage data, but expect heavy dilution and a long road ahead for this clinical-stage biotech.**

AI Summary

Palisade Bio, Inc. (PALI) is a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, with its lead product candidate, PALI-2108, targeting Inflammatory Bowel Disease (IBD), including fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC). The company recently completed a Phase 1 clinical study for PALI-2108, announcing positive safety, tolerability, and pharmacokinetic (PK) results on May 27, 2025, for healthy volunteers and on August 7, 2025, and September 17, 2025, for UC patients. All 5 UC patients in the cohort responded to treatment, showing promising signals of clinical improvement. PALI-2108 is a prodrug inhibitor designed to target PDE4 in colon tissues, aiming to reduce inflammation and fibrosis. The company plans to initiate an exploratory Phase 1b cohort in FSCD, followed by Phase 2 clinical programs for FSCD and moderate to severe UC, having received a No Objection Letter from Health Canada on September 5, 2025, for the FSCD Phase 1b cohort. This S-1 filing indicates an offering of 147,058,823 shares of common stock and pre-funded warrants, with the last reported sale price of common stock at $0.68 per share on September 24, 2025.

Why It Matters

This S-1 filing is critical for Palisade Bio as it seeks to raise capital to advance PALI-2108 into Phase 1b and Phase 2 trials for FSCD and UC, potentially addressing a significant unmet medical need in the IBD market. For investors, this offering represents an opportunity to participate in a clinical-stage biotech with promising early-stage data, but also carries substantial dilution risk given the large number of shares offered relative to the current market price of $0.68. The competitive landscape for IBD treatments is robust, with established players and numerous therapies, making PALI-2108's biomarker-based precision medicine approach a key differentiator if successful. Employees and customers could benefit from the continued development of a potentially effective, localized treatment for debilitating IBD conditions.

Risk Assessment

Risk Level: high — The risk level is high due to the company's clinical-stage nature, meaning no approved products and no revenue from product sales. The offering of 147,058,823 shares of common stock and pre-funded warrants, with an additional 8,823,529 Representative Warrants, represents significant potential dilution for existing shareholders, especially given the last reported sale price of $0.68 per share on September 24, 2025. Furthermore, the company operates in a highly competitive biopharmaceutical market, and the success of PALI-2108 is subject to extensive clinical trials and regulatory approvals.

Analyst Insight

Investors should approach PALI with extreme caution, recognizing the high-risk, high-reward profile of clinical-stage biotechs. Consider the significant dilution from this offering and the long timeline to potential market approval. Only investors with a high-risk tolerance and a long-term horizon should consider a position, and even then, it should be a small allocation within a diversified portfolio.

Financial Highlights

debt To Equity

Not disclosed

revenue

$0

operating Margin

Negative value not disclosed

total Assets

Not disclosed

total Debt

Not disclosed

net Income

Negative value not disclosed

eps

Negative value not disclosed

gross Margin

N/A

cash Position

Not disclosed

revenue Growth

N/A

Key Numbers

• 147,058,823 — Shares of common stock offered (Represents significant potential dilution for existing shareholders.)
• $0.68 — Last reported sale price of common stock (As of September 24, 2025, indicating the current market valuation.)
• $0.0001 — Exercise price of pre-funded warrants (Minimal exercise price for pre-funded warrants, making them almost equivalent to common stock.)
• 8,823,529 — Shares underlying Representative Warrants (Additional warrants issued to underwriters, contributing to potential dilution.)
• 22,058,823 — Over-allotment option shares (Additional shares underwriters can purchase, increasing the total offering size.)
• 5 — Number of UC patients in Phase 1 cohort (All 5 patients responded to PALI-2108 treatment, showing promising clinical activity.)
• 89 — Total subjects dosed in Phase 1 study (Across SAD, MAD, FE, and UC cohorts, demonstrating study completion.)
• October 9, 2024 — Date of Health Canada No Objection Letter for Phase 1 UC study (Enabled the commencement of the Phase 1 human clinical study.)
• September 5, 2025 — Date of Health Canada No Objection Letter for Phase 1b FSCD cohort (Allows the company to proceed with further clinical development for FSCD.)
• 6.0% — Percentage of shares for Representative Warrants (Represents the proportion of the offering allocated to underwriter compensation.)

Key Players & Entities

• PALISADE BIO, INC. (company) — Registrant and issuer of securities
• PALI-2108 (product) — Lead product candidate for IBD
• JD Finley (person) — Chief Executive Officer of Palisade Bio, Inc.
• Health Canada (regulator) — Issued No Objection Letters for PALI-2108 clinical studies
• Ladenburg Thalmann (company) — Underwriter for the offering
• The Nasdaq Capital Market (regulator) — Listing exchange for PALI common stock
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Jeffrey C. Thacker (person) — Counsel for Palisade Bio, Inc.
• Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (company) — Legal counsel for Palisade Bio, Inc.
• Michael Nertney (person) — Counsel for Palisade Bio, Inc.

FAQ

Risk Factors

• Significant Dilution from Share Offering [high — financial]: The company is offering 147,058,823 shares of common stock and pre-funded warrants, which represents a substantial increase in the total number of outstanding shares. This offering, at a last reported sale price of $0.68 per share, will significantly dilute existing shareholders' ownership percentages and potentially impact the stock price.
• Dependence on Future Financing [high — financial]: As a clinical-stage biopharmaceutical company, Palisade Bio has a history of operating losses and expects to incur significant expenses in the future, particularly for clinical trials and product development. The company's ability to continue as a going concern is dependent on its ability to secure additional funding through equity or debt financings, which may not be available on favorable terms or at all.
• Clinical Trial Risks and Delays [high — regulatory]: The success of Palisade Bio is heavily reliant on the successful development and regulatory approval of its product candidate, PALI-2108. Clinical trials are inherently risky, with potential for unexpected adverse events, lack of efficacy, or failure to meet endpoints. Delays in clinical development, such as obtaining regulatory approvals or completing trials, can significantly impact the company's timeline and financial resources.
• Competition in IBD Market [medium — market]: The market for Inflammatory Bowel Disease (IBD) treatments is highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing novel therapies. Palisade Bio will face competition from existing treatments and pipeline candidates, requiring PALI-2108 to demonstrate significant advantages in efficacy, safety, or cost to gain market share.
• Manufacturing and Supply Chain Risks [medium — operational]: Scaling up manufacturing processes for PALI-2108 to commercial levels presents operational challenges. Ensuring a reliable and cost-effective supply chain for raw materials and finished products is critical. Any disruptions or failures in manufacturing or supply could impede the company's ability to meet market demand.
• Pre-funded Warrants and Dilution [medium — financial]: The offering includes pre-funded warrants with a nominal exercise price of $0.0001, making them nearly equivalent to common stock. This structure allows investors to purchase shares at a lower upfront cost but will result in the same dilution as purchasing common stock directly upon exercise, further increasing the total potential share count.
• Uncertainty of Regulatory Approval [high — regulatory]: Despite positive Phase 1 results for PALI-2108, the drug must still undergo rigorous Phase 2 and Phase 3 clinical trials to demonstrate safety and efficacy for regulatory approval by agencies like the FDA and EMA. The path to approval is long, expensive, and uncertain, with no guarantee of success.
• Underwriter Warrants and Dilution [medium — financial]: The issuance of 8,823,529 shares underlying Representative Warrants to underwriters, representing 6.0% of the offering, adds to the potential dilution for existing shareholders. These warrants, if exercised, will further increase the number of outstanding shares.

Industry Context

Palisade Bio operates in the highly competitive biopharmaceutical sector, specifically targeting the inflammatory bowel disease (IBD) market. This market is characterized by significant unmet needs, particularly for patients with fibrostenotic complications, and is populated by both large pharmaceutical companies and numerous emerging biotech firms. Key trends include the development of targeted therapies that offer improved efficacy and safety profiles over existing treatments, as well as novel drug delivery mechanisms to enhance local action and reduce systemic exposure.

Regulatory Implications

The company faces significant regulatory hurdles inherent in drug development. Positive Phase 1 results for PALI-2108 are encouraging, but the path to FDA and other regulatory approvals requires successful completion of extensive and costly Phase 2 and Phase 3 trials. Any delays, unexpected safety signals, or failure to meet efficacy endpoints in these later-stage trials could halt development and pose substantial risks.

What Investors Should Do

1. Evaluate dilution impact carefully.
2. Monitor clinical trial progress closely.
3. Assess the competitive landscape.
4. Consider the company's cash burn and future financing needs.

Key Dates

• 2025-09-17: Announced positive safety, tolerability, and PK results for PALI-2108 in UC patients. — Provides early clinical validation for PALI-2108's potential in treating ulcerative colitis, a key target indication.
• 2025-09-05: Received No Objection Letter from Health Canada for Phase 1b FSCD cohort. — Enables the company to advance PALI-2108 into a new indication (fibrostenotic Crohn's disease) and further clinical development.
• 2025-08-07: Announced positive safety, tolerability, and PK results for PALI-2108 in UC patients. — Reinforces positive early-stage data for PALI-2108 in a specific patient population.
• 2025-05-27: Announced positive safety, tolerability, and PK results for PALI-2108 in healthy volunteers. — Demonstrates initial safety profile of PALI-2108, a prerequisite for further human studies.
• 2024-10-09: Received Health Canada No Objection Letter for Phase 1 UC study. — Allowed the company to initiate its first human clinical study for PALI-2108 in ulcerative colitis patients.
• 2025-09-24: Last reported sale price of common stock at $0.68. — Provides a current market valuation reference point for the company's stock prior to the offering.

Glossary

Prodrug

An inactive or less active form of a drug that is converted into its active form within the body. (PALI-2108 is a prodrug designed to be activated in the colon, potentially improving its targeted delivery and reducing systemic side effects.)

PDE4 Inhibitor

A drug that inhibits phosphodiesterase 4, an enzyme involved in inflammatory pathways. (PALI-2108 targets PDE4 in colon tissues to reduce inflammation and fibrosis, which are key mechanisms in IBD.)

Fibrostenotic Crohn's Disease (FSCD)

A subtype of Crohn's disease characterized by the narrowing of the intestine due to scar tissue formation (fibrosis). (FSCD is a specific, severe manifestation of Crohn's disease that Palisade Bio aims to treat with PALI-2108.)

Ulcerative Colitis (UC)

A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon. (UC is a primary indication for PALI-2108, with promising early results in Phase 1 studies.)

Pharmacokinetics (PK)

The study of how a drug is absorbed, distributed, metabolized, and excreted by the body. (Positive PK results indicate that PALI-2108 is behaving as expected in the body, supporting its further development.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase shares at a nominal price, effectively acting as a substitute for immediate share purchase, often used in offerings to provide immediate capital while deferring full share issuance. (These are part of the current offering and will convert into common stock, contributing to future share count and dilution.)

No Objection Letter

A formal communication from a regulatory authority (like Health Canada) indicating that they have no objections to the initiation of a proposed clinical trial. (These letters are critical milestones that permit the company to proceed with human testing of its drug candidates.)

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This S-1 filing details the company's business, financial condition, and the terms of the proposed securities offering.)

Year-Over-Year Comparison

This S-1 filing represents a significant event for Palisade Bio, marking its intention to raise substantial capital through a public offering. Unlike previous filings that may have focused on early-stage research and preclinical data, this document details a specific offering size (147,058,823 shares) and provides updated clinical progress, including positive Phase 1 results for PALI-2108 in various cohorts. The filing also highlights the company's progression towards later-stage clinical development, evidenced by the Health Canada No Objection Letter for the FSCD Phase 1b cohort.

Key Financial Figures

• $0.01 — 3 shares of our common stock, par value $0.01 per share (the “common stock&rdqu
• $0.0001 — he common stock in this offering, minus $0.0001. Each pre-funded warrant is exercisable
• $0.68 — rted sale price of our common stock was $0.68 per share. The assumed public offering
• $13.9 billion — market for CD treatments was valued at $13.9 billion in 2022 and is projected to grow to app
• $25.5 billion — d is projected to grow to approximately $25.5 billion in 2032 at a CAGR of approximately 6%.
• $7.3 billion — treatments was valued at approximately $7.3 billion in 2021 and is expected to grow to over
• $9.5 billion — in 2021 and is expected to grow to over $9.5 billion in 2031 at a compound annual growth rat

Filing Documents

• forms-1.htm (S-1) — 812KB
• ex1-1.htm (EX-1.1) — 264KB
• ex4-1.htm (EX-4.1) — 129KB
• ex4-2.htm (EX-4.2) — 133KB
• ex4-3.htm (EX-4.3) — 149KB
• ex5-1.htm (EX-5.1) — 20KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107.htm (EX-FILING FEES) — 41KB
• ex5-1_001.jpg (GRAPHIC) — 37KB
• forms-1_01.jpg (GRAPHIC) — 5KB
• forms-1_001.jpg (GRAPHIC) — 118KB
• forms-1_002.jpg (GRAPHIC) — 174KB
• 0001493152-25-015872.txt ( ) — 2167KB
• ex107_htm.xml (XML) — 17KB

Use of Proceeds

Use of Proceeds 36 Dividend Policy 38 Capitalization 39

Dilution

Dilution 41 Certain Relationships and Related Party Transactions 43

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 44

Description of Capital Stock

Description of Capital Stock 45

Description of Securities We are Offering

Description of Securities We are Offering 49

Underwriting

Underwriting 53 Legal Matters 57 Experts 58 Where You Can Find More Information 59 Incorporation of Certain Information by Reference 60 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Incorporation of Certain Information by Reference.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information by Reference,” before deciding to invest in our securities. Neither we nor the underwriters have authorized anyone to provide you with additional information or information different from that contained or incorporated by reference in this prospectus or in any free writing prospectus that we have authorized for use in connection with this offering. We take no responsibility for and cannot provide any assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer to sell to any person, or a solicitation of an offer to purchase from any person, the securities offered by this prospectus in any jurisdiction in which it is unlawful to make such offer or solicitation of an offer. The underwriters are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus and any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the respective dates thereof, and the information in the documents incorporated by reference in this prospectus is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations, and prospects may have changed since such dates. It is

View Full Filing

View this S-1 filing on SEC EDGAR